Compare · MRK vs MYNZ
MRK vs MYNZ
Side-by-side comparison of Merck & Company Inc. (MRK) and Mainz Biomed N.V. (MYNZ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and MYNZ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $334.43B, about 1790.7x MYNZ ($186.8M).
- Over the past year, MRK is up 63.8% and MYNZ is down 50.3% - MRK leads by 114.1 points.
- MRK has hit the wire 17 times in the past 4 weeks while MYNZ has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 4 for MYNZ).
- Company
- Merck & Company Inc.
- Mainz Biomed N.V.
- Price
- $135.59+2.02%
- $0.83+0.48%
- Market cap
- $334.43B
- $186.8M
- 1M return
- +9.75%
- +1.47%
- 1Y return
- +63.80%
- -50.30%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 17
- 0
- Recent ratings
- 25
- 4
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Mainz Biomed N.V.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Latest MRK
- EVP, Access, Policy & Comms Guindo Chirfi sold $1,350,000 worth of shares (10,000 units at $135.00), decreasing direct ownership by 21% to 36,613 units (SEC Form 4)
- EVP, General Counsel Zachary Jennifer exercised 54,927 shares at a strike of $109.78 and sold $10,718,495 worth of shares (80,315 units at $133.46), decreasing direct ownership by 36% to 45,509 units (SEC Form 4)
- EVP&Pres, Merck Animal Heallth Deluca Richard R. sold $5,942,369 worth of shares (45,320 units at $131.12), decreasing direct ownership by 29% to 110,167 units (SEC Form 4)
- Merck upgraded by Daiwa Securities with a new price target
- EVP&Pres, Merck Animal Heallth Deluca Richard R. sold $788,773 worth of shares (6,050 units at $130.38), decreasing direct ownership by 4% to 155,487 units (SEC Form 4)
- EVP & Pres. MMD Maraldo David R. exercised 18,706 shares at a strike of $82.25 and sold $2,407,797 worth of shares (18,706 units at $128.72) (SEC Form 4)
- EVP,Chief Info&Digital Officer Williams David Michael exercised 52,847 shares at a strike of $74.49 and sold $6,805,145 worth of shares (52,847 units at $128.77), increasing direct ownership by 0.00% to 31,716 units (SEC Form 4)
- EVP, Access, Policy & Comms Guindo Chirfi sold $1,965,000 worth of shares (15,000 units at $131.00), decreasing direct ownership by 24% to 46,613 units (SEC Form 4)
- SEC Form 10-Q filed by Merck & Company Inc.
- SEC Form 13F-HR filed by Merck & Company Inc.
Latest MYNZ
- SEC Form PRE 14A filed by Mainz Biomed N.V.
- Mainz Biomed N.V. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
- SEC Form 4 filed by Director Lazar David E.
- New insider Lazar David E. claimed no ownership of stock in the company (SEC Form 3)
- Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples
- Chief Financial Officer Caragol William J was granted 290,000 units of Ordinary Shares, increasing direct ownership by 372% to 367,899 units (SEC Form 4)
- Director Dreismann Heinrich was granted 45,000 units of Ordinary Shares, increasing direct ownership by 228% to 64,700 units (SEC Form 4)
- Director Tibbitts Gregory J was granted 45,000 units of Ordinary Shares, increasing direct ownership by 414% to 55,875 units (SEC Form 4)
- Chief Executive Officer Baechler Guido was granted 440,000 units of Ordinary Shares, increasing direct ownership by 267% to 605,058 units (SEC Form 4)